Antiostéoclastique And NotR. B. Wagman

List of bibliographic references

Number of relevant bibliographic references: 6.

Ident.	Authors (with country if any)	Title
000346	Roger M. Zebaze [Australie] ; Cesar Libanati [États-Unis] ; Matthew Austin [États-Unis] ; Ali Ghasem-Zadeh [Australie] ; David A. Hanley [Canada] ; Jose R. Zanchetta [Argentine] ; Thierry Thomas [France] ; Stephanie Boutroy [France] ; Cesar E. Bogado [Argentine] ; John P. Bilezikian [États-Unis] ; Ego Seeman [Australie]	Differing effects of denosumab and alendronate on cortical and trabecular bone
001317	Philip N. Sambrook [Australie] ; Christian Roux [France] ; Jean-Pierre Devogelaer [Belgique] ; Kenneth Saag [États-Unis] ; Chak-Sing Lau [Royaume-Uni] ; Jean-Yves Reginster [Belgique] ; Christina Bucci-Rechtweg [États-Unis] ; GUOQIN SU [États-Unis] ; David M. Reid [Royaume-Uni]	Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate
002701	David M. Reid [Royaume-Uni] ; Jean-Pierre Devogelaer [Belgique] ; Kenneth Saag [États-Unis] ; Christian Roux [France] ; Chak-Sing Lau [Royaume-Uni] ; Jean-Yves Reginster [Belgique] ; Philemon Papanastasiou [Suisse] ; Alberto Ferreira [Suisse] ; Florian Hartl [Suisse] ; Taiwo Fashola [Suisse] ; Peter Mesenbrink [États-Unis] ; Philip N. Sambrook [Australie]	Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON) : a multicentre, double-blind, double-dummy, randomised controlled trial
003270	John A. Eisman [Australie] ; Roberto Civitelli [États-Unis] ; Silvano Adami [Italie] ; Edward Czerwinski [Pologne] ; Chris Recknor [États-Unis] ; Richard Prince [Australie] ; Jean-Yves Reginster [Belgique] ; Mone Zaidi [États-Unis] ; Dieter Felsenberg [Allemagne] ; Claire Hughes [Suisse] ; Nicole Mairon [Suisse] ; Daiva Masanauskaite [Suisse] ; David M. Reid [Royaume-Uni] ; Pierre D. Delmas [France] ; Robert R. Recker [États-Unis]	Efficacy and Tolerability of Intravenous Ibandronate Injections in Postmenopausal Osteoporosis : 2-Year Results from the DIVA Study
003465	D. M. Reid [Royaume-Uni] ; D. Hosking [Royaume-Uni] ; D. Kendler [Canada] ; M. L. Brandi [Italie] ; J. D. Wark [Australie] ; J. F. Marques-Neto [Brésil] ; G. Weryha [France] ; N. Verbruggen [États-Unis] ; C. M. Hustad [États-Unis] ; E. M. Mahlis [États-Unis] ; M. E. Melton [États-Unis]	A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis : 24-month results from FACTS-International
003F35	Pierre D. Delmas [France] ; Silvano Adami [Italie] ; Cezary Strugala [Pologne] ; Jacob A. Stakkestad [Norvège] ; Jean-Yves Reginster [Belgique] ; Dieter Felsenberg [Allemagne] ; Claus Christiansen [Danemark] ; Roberto Civitelli [États-Unis] ; Marc K. Drezner [États-Unis] ; Robert R. Recker [États-Unis] ; Michael Bolognese [États-Unis] ; Claire Hughes [Suisse] ; Daiva Masanauskaite [Suisse] ; Penelope Ward [Suisse] ; Philip Sambrook [Australie] ; David M. Reid [Royaume-Uni]	Intravenous ibandronate injections in postmenopausal women with osteoporosis : One-year results from the dosing intravenous administration study

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024